Non-small-cell lung cancer is the leading cause of cancer death worldwide. Although radiotherapy is an effective treatment choice for early-stage cases, the 5-year survival rate of patients diagnosed in late-stages remains poor. Increasing evidence suggests that the local and systemic effects of radiotherapy dependent on the induced anti-tumor immune responses. We believe that an educated adaptation of radiotherapy plans based not only on the induced immune responses, but also on the tumor-immune ecosystem composition at the beginning of treatment might increase local tumor control. We propose two different mathematical models to evaluate the potential of the tumor-immune context to inform adaptation of treatment plans with the aim of improving outcomes.
I. BACKGROUND
Lung cancer is the second most common cancer, with an estimated of 224,390 new cases (117,920 in men and 106,470 in women) and 158,000 deaths in the US in 2016 [1] . About 24% of patients present with Stage III non-small cell lung cancer (NSCLC) for which chemoradiotherapy is the standard-of-care for inoperable cases. A systems biology model of tumor intrinsic radiosensitivity, radiosensitivity index RSI [2] , has been clinically evaluated in over 8,000 patients in multiple disease sites, including lung. Whilst 60% of stage III NSCLC patients with lower RSI values (RSI < 0.31) are controlled by radiation, treatment-resistant patients fail locoregionally with a 5-year overall survival of 5-14%. Patients with relapsed NSCLC are frequently reirradiated, rarely with improved outcomes. This offers an opportunity for investigating alternative radiation approaches, either alone or in combination with targeted agents.
Multiple altered radiation fractionation protocols, including the accelerated fractionation or hyperfractionation have been tested clinically without significant outcome improvements, in part due to (i) non-specific selection of patients into the different treatment protocols, and (ii) the prevailing dogma of delivering the same dose per fraction and constant fractionation intervals. Combination of radiation and targeted therapy, either concurrently or sequentially, has achieved significantly prolonged overall survival in patients with confirmed mutation status [3] . Compelling results are also emerging from clinical trials evaluating combination of radiotherapy with immunotherapy [3] . Interestingly, radiation therapy also induces cell stress and immunogenic cell death, thereby exposing a wealth of previously hidden tumorassociated antigens, heat shock or stress proteins (HSP) and danger-associated molecular patterns (DAMP), which are endogenous immune adjuvants that can elicit an antitumor immune response [4] . To date, radiation therapy and dose scheduling has not specifically focused on enhancing the immune response to tumor antigens. Here we propose a novel investigation in which we seek to exploit the immunostimulatory consequence of radiation therapy to induce de novo antitumor immune responses and augment the effect of blocking immunosuppression.
We hypothesize that the tumor-immune ecosystem composition at clinical presentation and its evolution during treatment contributes to clinical response to radiotherapy. Radiation-induced promotion of adaptive immunity, either stimulation of antitumor immunity or inhibition of immune regulatory mechanisms, may be required to overcome radiation resistance, particularly in Stage III NSCLC patients. It is conceivable that alternative radiation fractionation, either alone or in combination with targeted therapy, may better synergize with the host immune system to control tumors resistant to conventional protocols.
II. MATERIAL AND METHODS
Transformed cancer cells are confronted with an innate and adaptive immune surveillance. Tumor-associated antigens (HSPs and DAMPs) released during cell death are endogenous immune adjuvants that can both initiate and continually stimulate an immune response against tumors. In retaliation, tumors can hijack intrinsic immune regulatory programs that are intended to prevent autoimmune disease, thereby facilitating continued growth despite the activated antitumor immune response. Irradiation induces cell stress and immunogenic cell death, thereby exposing a wealth of previously hidden and new tumor associated antigens to the immune system. However, radiation also induces cell death in the tumor inhibiting and immune inhibiting immune populations, which makes predicting radiation response a complex dynamical system that could be best understood with the help of mathematical modeling (Figure 1 ). To that 
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A role for VEGF in abnormal DC differentiation was first demonstrated in vitro 93 and addition of neutralizing VEGF antibodies resulted in normal maturation of DCs 93 . These initial in vitro findings were confirmed in vivo. Administration of recombinant VEGF to tumourfree mice resulted in defective DC development and an accumulation of Gr-1 + (also know as LY6G + ) immature myeloid-derived suppressor cells 101 . Furthermore, pretreatment of mice with VEGF inhibited FLT3 ligand stimulation of DC differentiation from bone marrow progenitor cells 102 . Treatment of tumour-bearing mice with neutralizing VEGF antibodies resulted in an increased number of spleen and lymph node DCs and improved DC differentiation 101,102 . Treatment with VEGF-targeted antibodies was also shown to improve anti-tumour peptide cytotoxic T-lymphocyte responses and efficacy of tumour immunotherapy in mouse models 102 . Thus, VEGF is a strong negative modulator of DC function in the tumour microenvironment, which contributes to immune privilege of tumours in the host. The potential pathways through which VEGF can inhibit DC differentiation have been investigated
.
These preclinical findings suggest that blockade of VEGF signalling could improve anti-tumour responses in patients through improvement in DC function and immune recognition of tumour cells. Although intriguing, this hypothesis has been studied only to a limited extent clinically.
In a phase I study of VEGF trap, DC and immune function was tested in 15 patients 103,101 . VEGF trap did not affect the total population of DCs, their myeloid or plasmacytoid subsets, myeloid-derived suppressor cells or regulatory T cells. VEGF trap did appear to significantly increase the fraction of mature DCs, suggesting that DC differentiation was improved in these patients. However, VEGF trap treatment was not associated with an overall increase in non-specific or antigen-specific T-cell responses. As these results were generated in a small patient cohort, it is difficult to draw conclusions from these data. Clearly, additional studies in larger patient populations are warranted to fully understand the importance of VEGF-targeted therapy on immune function in cancer patients. It will also be important to study VEGF-targeted therapy in combination with other tumour immunotherapy strategies, such as anti-CTLA4 and tumour vaccine therapies, that directly aim to enhance the immune response against tumours.
Counteracting VEGF and/or EPC upregulation One mechanism by which VEGF-targeted therapy may be of benefit to patients is by counteracting the upregulation of VEGF expression following genotoxic stress induced by chemotherapy or radiation therapy. VEGF expression is upregulated by variations in the microenvironment that are associated with stress, such as hypoxia, low pH and nutrient deprivation. Genotoxic stress induced by chemotherapy and radiation therapy has also been found to induce VEGF expression.
Human melanoma cells treated with dacarbazine led to an increase in secreted VEGFA and interleukin 8 (IL8) 102 . In these studies, the authors found an induction of VEGF levels and increased promoter activity. In a follow-up study, this group showed that dacarbazineresistant melanoma cell lines demonstrated increased growth in vivo with increased microvessel density 103 . Others have shown that ultraviolet irradiation or photodynamic therapy can increase tumour cell VEGF secretion from keratinocytes or prostate cancer cells, respectively 104 . Lastly, irradiated tumour cells were shown to have increased expression levels of VEGF. Importantly, sublethal irradiation actually led to an induction of in vivo tumour growth hypothesized to be secondary to increased VEGF secretion 102 . Our laboratory has recently shown that oxaliplatin induces VEGFA and other members of the VEGF family of ligands including PlGF and VEGFC. We also studied the effect of acute exposure (6-24 h) of oxaliplatin in induction of VEGF receptors on tumour cells, and found that VEGFR1 is induced by oxaliplatin exposure. Thus, one proposed mechanism of action of VEGFtargeted therapy is to offset induction of VEGF signalling, presumed to be survival signals for tumour cells.
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Numerous studies have examined the stability and longevity of activated macrophages within the host. Several in vivo studies suggest that the phenotype of a macrophage population can change over time. It is not clear whether this phenotypic alteration is the result of de-differentiation of the original macrophages back to the resting state or of the migration of a new population of macrophages into the tissue site where they replace the original cells. Regardless of the mechanism, there are some cases in which a phenotypic switch in the macrophage population occurs over time and is associated with pathology. Two specific examples of this phenotypic switch are discussed in detail below.
Cancer: switching from classically activated to regulatory macrophages. The role of macrophages in cancer has been controversial and many aspects remain unresolved. Early evidence showed that macrophage surveillance mechanisms are essential for preventing the growth of transformed or pre-transformed cells, and there is evidence showing that activated macrophages can kill transformed cells in vitro 79 . However, there is also evidence that macrophage depletion has little effect on the host's susceptibility to cancer and in some cases may even be beneficial to the host (for reviews, see REFS 80, 81) . We propose that macrophages can have contrasting roles in cancer depending on their phenotype.
Classically activated macrophages have the potential to contribute to the earliest stages of neoplasia 82 , primarily because the free radicals that they produce can lead to the DNA damage; this causes mutations that can predispose host cells to transformation. An anecdotal example of this macrophage-mediated induction of tumorigenesis is the neoplasia that is associated with old tuberculosis scars in the lungs of previously infected patients. Classically activated macrophages accumulate in these scars, damage host tissue and induce cellular transformation. This scenario is in contrast to early in vitro studies, which convincingly showed that classically activated macrophages were cytotoxic to tumour cells but not to normal cells and therefore suggested that classically activated macrophages contributed to the early eradication of transformed cells 83 . Thus, although there is controversy about the roles of macrophages in the earliest stages of cancer, there seems to be general agreement that these cells resemble classically activated macrophages that have an inflammatory phenotype.
However, as tumours progress and grow, the tumour microenvironment markedly influences tumourassociated macrophages. These macrophages change their physiology and take on a phenotype that more closely resembles regulatory macrophages 84 . The tumourderived agents that induce the development of these regulatory macrophages have not been identified, but candidates include prostaglandins, hypoxia, extra cellular nucleotides, apoptotic cells, hyaluronan fragments and IgG 85-88 , which may work synergistically within the tumour microenvironment. Recent studies indicate that the induction of a suppressive macrophage population in tumours may occur through the MyD88-dependent activation of NF B 89 . Irrespective of the stimulus, these tumour-associated macrophages produce high levels of IL-10, can inhibit immune responses to neo-antigens that are expressed by tumour cells and can de-activate neighbouring macrophages 71 . Recent studies also suggest that regulatory macrophages can contribute to angiogenesis and thereby promote tumour growth 90 .
A phenotypic characterization that encompasses all tumour-associated macrophages has yet to emerge, but it is clear that they exhibit several characteristics of regulatory macrophages, including the production of high levels of IL-10 but little or no IL-12 (REFS 71, 90) . However, they also seem to be defective in TNF production and they may suppress the activity of antigen-presenting cells. Therefore, although these cells share many characteristics of regulatory macrophages, they also have some of the Nature Reviews | Immunology Classically activated macrophages produce high levels of interleukin-12 (IL-12) and modest levels of IL-10. By contrast, regulatory macrophages produce high levels of IL-10 and low levels of IL-12. Macrophages treated with IL-4 (that is, wound-healing macrophages) produce low levels of these cytokines, but express resistin-like molecule-(RELM ) intracellularly, a marker that is not expressed by the other macrophage populations. Treatment of IL-4-primed macrophages with lipopolysaccharide (LPS) and immune complexes results in a hybrid phenotype in which the cells continue to express RELM (similarly to wound-healing macrophages) but also produce high levels of IL-10 (similarly to regulatory macrophages).
ECEMBER 2008 | VOLUME 8 www.nature.com/reviews/immunol ctivated to regulatory phages in cancer has ts remain unresolved. rophage surveillance enting the growth of cells, and there is eviophages can kill transthere is also evidence tle effect on the host's e cases may even be , see REFS 80, 81) . We ve contrasting roles in ype. ges have the potential s of neoplasia 82 , prihat they produce can es mutations that can ation. An anecdotal ediated induction of at is associated with of previously infected rophages accumulate e and induce cellular in contrast to early gly showed that clase cytotoxic to tumour erefore suggested that s contributed to the ells 83 . Thus, although es of macrophages in e seems to be general le classically activated atory phenotype. and grow, the tumour influences tumourmacrophages change henotype that more phages 84 . The tumourevelopment of these t been identified, but Therefore, although these cells share many characteristics of regulatory macrophages, they also have some of the Nature Reviews | Immunology Classically activated macrophages produce high levels of interleukin-12 (IL-12) and modest levels of IL-10. By contrast, regulatory macrophages produce high levels of IL-10 and low levels of IL-12. Macrophages treated with IL-4 (that is, wound-healing macrophages) produce low levels of these cytokines, but express resistin-like molecule-(RELM ) intracellularly, a marker that is not expressed by the other macrophage populations. Treatment of IL-4-primed macrophages with lipopolysaccharide (LPS) and immune complexes results in a hybrid phenotype in which the cells continue to express RELM (similarly to wound-healing macrophages) but also produce high levels of IL-10 (similarly to regulatory macrophages).
www.nature.com/reviews/immunol Fig. 1 . Diagram of the system interactions between tumor, immune effector and immune regulatory and the response to radiation therapy. end, we develop an agent-based model (ABM) to account for the spatial aspects of tumor growth and immune cell dynamics, as well as formulate an ODE model with the potential to scale up to realistic cell population sizes.
ODE model We define the system variables as cancer (T ), immune effector (E) and immune regulatory (R) cells, and their respective dynamics with
where the functions F λ represents the net tumor growth, ABM model. To capture spatial interactions between cells, we simulate the tumor-immune ecosystem under radiotherapy using a lattice-based agent-based model (ABM). Cells are individually represented and its fates determined by mechanistic rules. Each cell in the model is capable of proliferate. Moreover, immune effector cells are capable of killing tumor cells by direct contact. Similarly, immune regulatory cells can kill effector cells by direct contact. The ABM model also accounts for the RSI values corresponding to lung cancer [2] , as well as the recruitment of effector and regulatory cells to the tumor region.
III. RESULTS
Preliminary Results of the ODE and ABM models indicate that the regulatory to effector cell ratio (Treg/Teff) has a significant impact on the success of radiation therapy. Figure 2 Fig. 2 . ODE model for tumor-immune dynamics under radiotherapy. Results from simulations with a low (left) and high (right) recruitment rate of regulatory cells. and 3 show the tumor and immune cell evolution before and after radiotherapy for different recruitment rates of regulatory cells. We found that increasing values of Treg/Teff adversely impact treatment outcomes by reducing the effectiveness of radiation therapy, i.e. the tumor microenvironment exhibits stronger suppressive activity mediated by regulatory cells. These in silico findings suggest that a personalized treatment adaptation based on the pre-treatment tumor-immune ecosystem and its evolution during radiation therapy might result in better outcomes. Fig. 3 . Lattice-based ABM model for tumor-immune dynamics under radiotherapy. Results from simulations with a low (top) and high (bottom) recruitment rate of regulatory cells. Filled region represents 95% confidence interval for 100 different simulations for the same initial conditions.
IV. DISCUSSION & FUTURE WORK
Preliminary model simulations provide a proof-of-concept demonstration of the importance of tumor-immune ecosystem dynamics in determining clinical response to radiotherapy. This lays the foundation for investigations into adaptive therapy to overcome radiation resistance in patients who failed conventional treatment. Whilst future translation of project findings into the clinic would most likely be for the subgroup of locally recurrent Stage III NSCLC patients subject to re-irradiation, we anticipate this project to also provide novel insights into combining RSI and immune infiltration evaluation to identify individual patients who are likely to fail conventional therapy, and thus are likely candidates for immediate treatment adaptation.
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